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Abstract
Background: ADAMTS19 encodes a member of the ADAMTS (a disintegrin and metalloproteinase domain with
thrombospondin motifs) protein family with emerging roles in carcinogenesis and metastasis. ADAMTS shares several
distinct protein modules including a propeptide region, a metalloproteinase domain, a disintegrin-like domain, and a
thrombospondin type 1 (TS) motif. In a previous work, we found ADAMTS19 frequently hypermethylated in colorectal
cancer (CRC). We explored the association of methylation with tumor genotype and phenotype.
Results: The methylation status of the CpG island in the promoter of ADAMTS19 was determined in 252 colorectal,
65 pancreatic, 33 breast and 169 ovarian primary tumors, 70 CRC metastases, and 10 CRC cell lines. Tumor-specific
methylation of ADAMTS19 was significantly more frequent in gastrointestinal than in gynecological cancers (odds ratio
(OR) = 2.9, confidence interval (CI) = (1.9–4.7), p = 5.2 × 10−7) and was independent of the methylation of adjacent loci
in CRC. Hypermethylation associated with CRC with mutated BRAF oncogene (OR = 10.1, CI = (3.1–42.9), p = 6.3 × 10−6)
and with the mucinous phenotype in CRC (OR = 2.1, CI = (1.1–4.1), p = 0.023) and ovarian cancer (OR = 60, CI = (16–346),
p = 4 × 10−16). Methylation was significantly more frequent in CRC metastases homing to the ovary and omentum than
in those homing to the liver and lung (OR = 6.1, CI = (1.8–22.2), p = 0.001). Differentiating local from distant metastatic
spread, methylation negatively associated with tumor progression (p = 0.031) but positively with depth of invasion
(p = 0.030). Hypermethylation associated with transcriptional repression in CRC cell lines, and treatment with 5′-AZA-2′-
deoxycytidine led to reactivation of mRNA expression. shRNA-mediated silencing of ADAMTS19 had no effect on the in
vitro proliferation rate of CRC cells but significantly diminished their collective migration speed (56 %, p = 3.3 × 10−4) and
potential to migrate in collagen I (64 %, p = 4.3 × 10−10).
Conclusions: Our results highlight the frequent involvement of ADAMTS19 epigenetic silencing in CRC and mucinous
ovarian cancer. The mechanistic preferences for the target organ of metastatic spread may lead to the development of
diagnostic CRC biomarkers. The association with the mucinous phenotype also may have diagnostic applications for
ovarian cancer.
Keywords: ADAMTS, Methylation, Matrix metallopeptidases, Gastrointestinal cancer, Ovarian cancer, MS-AFLP
* Correspondence: mperucho@imppc.org
1Institute of Predictive and Personalized Medicine of Cancer (IMPPC), Institut
d’investigació en ciéncies de la salut Germans Trias I Pujol, (IGTP), Campus
Can Ruti, 08916 Badalona, Barcelona, Spain
2Sanford Burnham Prebys Medical Dicovery Institute, 10901 N. Torrey Pines
Rd. La Jolla, San Diego, CA 92037, USA
Full list of author information is available at the end of the article
© 2015 Alonso et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Alonso et al. Clinical Epigenetics  (2015) 7:124 
DOI 10.1186/s13148-015-0158-1
Background
Colorectal cancer (CRC) is the third most common cancer
for men and women worldwide with over 1.3 million new
cases diagnosed in 2012 [1]. Despite decreasing trends in
incidence and mortality in the last decade, CRC still is the
third cause of cancer-related deaths accounting for near
10 % of total cancer mortality worldwide [1]. Metastatic
disease is the major cause of death in CRC. The metastatic
dissemination involves the acquisition by the malignant
cell of an abnormal loss of the tridimensional homeostatic
tissue organization. Metastatic spread is a complex multi-
step process that includes several sequential steps: inva-
sion through the extracellular matrix (ECM), migration,
epithelial-mesenchymal transition (EMT), angiogenesis,
the ability to survive without the contact with other sister
cells (“anoikis”), colonization, and resistance to adverse
tissue environments [2, 3]. CRC metastasizes most com-
monly to the liver, the lung, and the peritoneal cavity, and
the histological cancer subtypes and tumor location influ-
ence the patterns of metastatic spread [3, 4]. Dissemin-
ation of metastases in CRC can be roughly classified
as via the lymphatic and circulatory systems to distant
organs—rectal cancers with tendency for homing to the
lung and colon cancers with preferential dissemination to
the liver—or via local mesothelial spread of floating cancer
cells to the peritoneal surfaces including the omentum
and proximal organs [5]. While the first two dissemination
ways involve intravasation and extravasation, the third
may not, but little is known about the molecular mecha-
nisms that may underlie these different metastatic spread
behaviors.
Alterations in the ADAMTS (a disintegrin and metallo-
proteinase domain with thrombospondin motifs) extracel-
lular matrix metallopeptidases contribute to tumorigenesis
and tumor progression [6–8]. The human ADAMTS family
encompasses 19 multidomain extracellular matrix metallo-
peptidases that participate in a wide range of physiological
processes, including ECM assembly and degradation,
homeostasis, organogenesis, and angiogenesis [7, 9]. The
first member of this family, ADAMTS1, was cloned in 1997
during a screening of genes selectively expressed on a mur-
ine cachexigenic tumor cancer cell line [10]. Multiple other
ADAMTS genes were later isolated and characterized by
several groups [11–21]. ADAMTS enzymes are closely
related to the members of the ADAM (a disintegrin and
metalloproteinase domain) family of metallopeptidases.
However, ADAMTS contain additional thrombospondin
type 1 motifs (TSP1) in their sequence. TSP1 motifs
are involved in the interaction with glycoconjugates
such as heparin and heparan sulfate that are present
in the ECM [22, 23]. The physiological substrates of
the ADAMTS family members include the propeptides
of type I collagen (ADAMTS2 and ADAMTS14), type
II collagen (ADAMTS2 and ADAMTS143), aggrecan
(ADAMTS1, ADAMTS4, ADAMTS5, ADAMTS9, and
ADAMTS12), versican (ADAMTS9), alpha-2-macroglobulin
(ADAMTS12), and von Willebrand Factor multimers
(ADAMTS13).
According to their physiological functions, ADAMTS pro-
teins have been grouped into anti-angiogenesis (ADAMTS1
and ADAMTS8), aggrecanases (ADAMTS1, ADAMTS4,
ADAMTS5, ADAMTS8, ADAMTS9, and ADAMTS15),
procollagen N-proteinases (ADAMTS2, ADAMTS3,
and ADAMTS14), GON-ADAMTS (ADAMTS9 and
ADAMTS20), and the von Willebrand factor cleaving
protease (vWCFP, ADAMTS13) [9]. The physiological
function and the substrates of ADAMTS6, ADAMTS7,
ADAMTS12, and ADAMTS16 to ADAMTS19 remain
uncharacterized.
Albeit some experimental data suggests a pro-
tumorigenic/metastatic function of ADAMTS proteins, par-
ticularly in the case of ADAMTS1, the majority of the re-
sults indicate that these proteins have a negative effect on
tumor progression [7, 8, 24, 25]. Frequent alterations in the
expression of these genes have been found in breast
cancer, the majority being downregulated (ADAMTS1,
ADAMTS3, ADAMTS5, ADAMTS8, ADAMTS9,
ADAMTS10, ADAMTS12, and ADAMTS18) but some
being upregulated (ADAMTS4, ADAMTS6, and
ADAMTS14) [26]. In addition, mutational inactivation,
and more frequently, transcriptional silencing by pro-
moter hypermethylation of ADAMTS genes have been
found in different types of cancer [8, 27–32]. We recently
reported that promoter hypermethylation of ADAMTS14
takes place not only in the tumors but also in the non-
cancerous colonic mucosa of CRC patients. The methyla-
tion of normal colonic mucosa was particularly present in
elder African-Americans, suggesting that it is an early
event in the carcinogenesis process and a diagnostic
marker of a field for cancerization [33]. Nothing is essen-
tially known about the function of ADAMTS19 or its pos-
sible role in cancer.
DNA methylation is an epigenetic mechanism with a
profound modulating effect on cellular gene expression pat-
terns. Under normal physiological conditions, it plays a cru-
cial role in establishing cell identity during development
and cell proliferation. In many human cancers, however,
the normal DNA methylation profile is substantially altered.
These alterations comprise both abnormal low levels of
genome-wide methylation (DNA hypomethylation) and
high levels of methylation in other loci (DNA hypermethy-
lation) [34]. Cancer-related DNA hypomethylation mainly
occurs in DNA repetitive elements and pericentromeric re-
gions, a phenomenon known to trigger genomic instability
[35]. In some cases, DNA hypomethylation has been also
found in unique loci leading to transcriptional reactivation
[36]. Cancer-related DNA hypermethylation mainly occurs
in CpG islands (CGI) associated with gene promoters and
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is generally accompanied by transcriptional silencing [37].
Since the discovery of the epigenetic inactivation of the
tumor suppressor Rb in the late 80s [38], a large number of
genes have been found to undergo somatic promoter
hypermethylation in human cancer, many of them with
tumor suppressor or DNA repair functions [39].
The low or no transcriptional activity of genes with
hypermethylated promoter-associated CGI associates with
the recruitment of chromatin remodeler complexes that
lead to a closed chromatin state [40]. However, after years
of intensive research, the primal cause of CGI hyperme-
thylation remains to be defined. The Polycomb (PcGs)
and Thritorax (TrxG) group proteins have been suggested
to be mechanistically involved in this cancer-specific ab-
normal hypermethylation, based on the enrichment of
PcGs target genes among the genes frequently hyper-
methylated in cancer [41]. Nevertheless, the reason why
some genes may undergo hypermethylation while others
do not remains as mysterious today as it was in the over
15-years-old original proposal [42]. The strong association
of methylation with mutations in BRAF in CRC [43] and
isocitrate dehydrogenase 1 gene (IDH1) in gliomas [44]
provides interesting clues but as indirect pleiotropic ef-
fects, rather than direct mechanistic causal relationships.
In this report, we characterized the promoter region of
ADAMTS19 frequently hypermethylated in CRC [45]
and extended this observation to other cancers. We cor-
related methylation with cancer genotype and with clini-
copathological parameters, especially the metastatic
homing preference. We also studied in vitro the effect of
ADAMTS19 transcriptional silencing in CRC phenotype.
Results
Hypermethylation of ADAMTS19 5′ CpG island in
gastrointestinal primary tumors
This study spawns from a previous work where we analyzed
methylation alterations in colorectal and gastric cancers by
methylation-sensitive amplification length polymorphism
(MS-AFLP). This is a DNA fingerprinting technique based
on the methylation-sensitive cleavage of NotI, a restriction
endonuclease that contains in its recognition sequence two
CpG dinucleotides [45]. A MS-AFLP band named C-19
was the most frequent hypermethylated in both gas-
tric (38/89, 42.7 %) and colorectal (25/73, 34.2 %) cancers
[45]. The C-19 band was mapped (see Methods) to the 5′
region of the ADAMTS19 gene (Fig. 1a).
We confirmed that methylation alterations of the
ADAMTS19 CGI were responsible for the changes in in-
tensity of band C-19 (Additional file 1: Figure S1) [46].
We also analyzed the association between hypermethyla-
tion identified by MS-AFLP (which is reflected by weaker
intensity of the fingerprint bands) and copy number
changes. ADAMTS19 is located in chromosome 5q,
16.8 Mb telomeric to tumor suppressor APC, frequently
lost in CRC. Over 50 cases were analyzed for loss of
heterozygosity (LOH) and copy number changes in 5q
by microallelotyping and array comparative genomic
hybridization (CGH) (Additional file 1: Figure S2). There
was no association between copy number alterations and
the MS-AFLP scoring, showing that band C-19 changes
reflected methylation alterations rather than genomic loss
of ADAMTS19.
We studied the extent of hypermethylation of
ADAMTS19 in 15 CRCs by bisulfite sequencing [47, 48].
The results confirmed that hypermethylation of ADAMTS19
was exclusive of the tumor tissues and extended through-
out the gene promoter region (Fig. 1b). Thus, we used
combined bisulfite and restriction analysis (COBRA), a
simpler and less expensive method (Fig. 1c), to complete
the analysis of 42 colonic adenomas, 210 primary CRCs,
70 metastases (Table 1), and their corresponding normal
tissues (for every patient, we analyzed both the tumor and
the colonic normal mucosa). ADAMTS19 was hyper-
methylated in 48 % of adenomas, 35 % of adenocarcin-
omas, and 31 % of metastases but never in the 322 normal
tissues corresponding to the tumoral samples.
ADAMTS19 hypermethylation is independent of
hypermethylation of surrounding CpG islands
We studied the methylation of the chr5 123.8–133.8 Mb
ADAMTS19 region in 35 CRCs and their matching nor-
mal tissues using Illumina HM450K methylation arrays.
The concordance between the COBRA scoring and the
Illumina HM450K arrays data was 100 %. Within the
3.5 Mb chromosomal region around ADAMTS19, there
are ten CGI (Fig. 2). The genes fibrillin 2 (FBN2) and
SLC27A6 (a fatty acid transporter) CGIs, located 0.9 and
0.5 Mb upstream of ADAMTS19, respectively, were con-
comitantly hypermethylated. chondroitin sulfate synthase
3 (CHSY3) located 0.45 Mb downstream of ADAMTS19
was also hypermethylated in some tumors. There was no
correlation between methylation of ADAMTS19 CGI and
methylation of any of these three genes (Fig. 2), indicating
that ADAMTS19 hypermethylation was an independent
event and not a secondary effect of hypermethylation in
the neighboring chromosomal region.
ADAMTS19 hypermethylation and clinicopathological and
molecular parameters in CRC
ADAMTS19 methylation in primary CRC did not associ-
ate with gender, race, age, or tumor location (Fig. 3a and
Additional file 1: Figure S3). We found, however, a posi-
tive association with MSI status (odds ratio (OR) = 2.7,
confidence interval (CI) = (1–7.3), p = 0.035) and with
BRAF mutations (OR = 10, CI = (3.1–42.9), p = 6.3 × 10−6)
(Fig. 3b). In a multivariate logistic regression analysis
including MSI and BRAF as factors, the association
with BRAF mutation retained statistical significance
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(OR = 10.5, CI = (3.3–43.2), p = 2.7 × 10−4) while the asso-
ciation with MSI status did not (OR = 0.94, CI = (0.27–
2.83), p = 0.91).
ADAMTS19 hypermethylation profile in gastrointestinal
and gynecological cancers
To investigate whether ADAMTS19 hypermethylation
was exclusive of gastric and colorectal cancers, we ana-
lyzed 356 primary tumor samples from other malignan-
cies. ADAMTS19 hypermethylation was more frequent
in cancers of gastrointestinal origin (stomach, colon,
and pancreas) than ovarian and breast cancers (OR = 2.9,
CI = (1.9–4.7), p = 5.2 × 10−7, Fig. 4a).
Analysis of the methylation data from the Cancer Gen-
ome Atlas (TCGA) validated our findings (Fig. 4b). In the
TCGA datasets ADAMTS19 was frequently hypermethy-
lated in gastrointestinal cancers including stomach (47.6–
53.7 %), esophageal (39.8 %), liver (30.9 %), colorectal
(22.2–25.2 %), and pancreatic cancers (13.8 %). In con-
trast, methylation incidence was much lower in breast
(1.5–2.5 %), ovarian (1 %), or prostate (0.5 %) cancers. The
TCGA data also confirmed the strong association between
ADAMTS19 hypermethylation and BRAF mutations in
220 CRCs (OR = 30.2, CI = (8.3–167), p = 4.4 × 10−11).
ADAMTS19 hypermethylation associated with the mucin-
ous phenotype in primary CRCs (OR= 2.1, CI = (1.1–4.2),
Fig. 1 Bisulfite sequencing of exon1 of ADAMTS19 in 15 CRC cases. a Scheme of the 600 bp region surrounding the first exon of ADAMTS19. The
transcriptional start site (TSS) and 5′ untranslated region (UTR) are indicated. In pink is an internal region of the ADAMTS19 CpG island (CGI), with vertical
bars indicating every CpG site. The dashed blue area indicates the band C-19 initially detected by MS-AFLP. The region amplified for bisulfite sequencing is
represented by the gray rectangle, with the BstUI sites indicated by vertical bars. For a larger view of this region, see Additional file 1: Figure S1. b On the left
side are cases that were scored as unmethylated by MS-AFLP. On the right are cases that were scored as hypermethylated. Every horizontal line represents
individual cloned sequences. Every circle represents 1 of the 34 CpG sites within the region studied. The scale is relative to the codon +1. In black and white,
represented are the methylated and unmethylated CpG sites, respectively. Cases with asterisks are included in the representative results of the BstuI COBRA
analysis (c). MWM molecular weight marker (100 bp ladder), N normal sample, T tumor sample, C+ positive control (human methylated DNA), C− negative
control (human non-methylated DNA), U undigested, D digested. Methylation is indicated by the presence of smaller digestion products
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Table 1 Demographics and clinical characteristics of the patients and samples analyzed in this study
Adenomas Carcinomas Metastases Carcinomas vs.
MetastasesNumber 42 210 70
Age n = 42 n = 210 n = 66
Mean ± SD 64.2 ± 11.4 65.1 ± 14.1 62.5 ± 11.5 p = 0.12
Range 30–80 18–93 33–86
Gender n = 42 n = 210 n = 66
Female 13 (31 %) 98 (47 %) 28 (40 %)
Male 29 (69 %) 112 (53 %) 38 (54 %) p = 0.57
Information not available 4 (6 %)
Race n = 27 n = 161 n = 63
Caucasian 18 (43 %) 125 (60 %) 57 (81 %)
African-American 9 (21 %) 36 (17 %) 6 (9 %) p = 0.035
Other/not well defined 15 (36 %) 49 (23 %) 7 (10 %)
Locationa n = 40 n = 210 n = 32
Proximal 27 (64 %) 110 (52 %) 9 (13 %)
Distal 13 (31 %) 100 (48 %) 23 (33 %) p = 0.013
Information not available 2 (5 %) 0 38 (54 %)
Stage (Dukes’) n = 210
A NA 18 (9 %) NA
B NA 77 (37 %) NA
C NA 59 (28 %) NA
D NA 56 (27 %) NA
Grade n = 202 n = 32
Well/moderate NA 156 (74 %) 32 (46 %)
Poor NA 46 (22 %) 2 (3 %) p = 0.021
Information not available NA 8 (4 %) 36 (51 %)
Mucinous phenotype n = 210 n = 70
Non-mucinous 151 (72 %) 57 (81 %)
Mucinous 59 (28 %) 13 (19 %) p = 0.15
MSI n = 41 n = 208 n = 62
MSS 40 (95 %) 185 (88 %) 62 (89 %)
MSI 1 (2 %) 23 (11 %) 0 p = 0.003
Information not available 1 (2 %) 2 (1 %) 8 (11 %)
TP53 n = 33 n = 191 n = 42
WT 28 (67 %) 104 (50 %) 18 (26 %)
MUT 5 (12 %) 87 (41 %) 24 (34 %) p = 0.23
Information not available 9 (21 %) 19 (9 %) 28 (40 %)
KRAS n = 42 n = 195 n = 50
WT 19 (45 %) 117 (56 %) 32 (46 %)
MUT 23 (55 %) 78 (37 %) 18 (26 %) p = 0.63
Information not available 0 15 (7 %) 20 (29 %)
BRAF n = 12 n = 175 n = 34
WT 12 (29 %) 153 (73 %) 32 (46 %)
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Table 1 Demographics and clinical characteristics of the patients and samples analyzed in this study (Continued)
MUT 0 22 (10 %) 2 (3 %) p = 0.38
Information not available 30 (71 %) 35 (17 %) 36 (51 %)
For every parameter, the number of cases with information is indicated (n=)
NA not applicable
aIn the metastases column, location refers to the originating primary lesion when known
P values of the comparison between carcinomas and metastases were obtained by Fisher’s test except for Age, where Student’s t test was applied
Fig. 2 Methylation analysis of the 3.5 Mb region of chromosome 5 surrounding the ADAMTS19 TSS in colorectal normal samples (upper heatmap)
and tumors (middle heatmap) from 35 CRC patients. Columns and rows in the heatmaps represent Illumina HM450K probes and tissue samples,
respectively. Samples are ordered according to the methylation level of the ADAMTS19 CGI. The lower heatmap shows the somatic difference in
methylation between tumor samples and their matching normal samples. In this region, there are ten CpG islands (gray bars), corresponding to
the promoters of SLC12A2, FBN2, SLC27A6, ISOC1, ADAMTS19, CHSY3, HINT1, LYRM7, and CDC42SE2 genes, as well as an intergenic CGI overlapping
with a CTCF binding site (indicated by an asterisk). The lower triangle shows the correlations between every pair of probes. Only correlations with
r2 > 0.25 (p < 0.01) are shown. The areas corresponding to the correlations with ADAMTS19 CGI are indicated with dashed line rectangles
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p = 0.023). A much stronger association was observed
in ovarian cancers (OR = 60, CI = (16–346), p = 3.9 ×
10−16). None of the serous or endometrioid type tu-
mors, which are the most frequent types of ovarian
cancer, exhibited ADAMTS19 hypermethylation (Fig. 4c).
The only other three methylated cases in the non-
mucinous subgroup of ovarian cancer were clear-cell
tumors.
ADAMTS19 methylation associates with local, but not with
distant, CRC metastases
ADAMTS19 hypermethylation was frequent in adenomas
and showed a trend for decreasing frequency during
tumor progression (Fig. 5a). ADAMTS19 methylation was
significantly higher in local metastases to the omentum
and ovary than to distant organs, the liver and lung (OR =
6.1, CI = (1.8–22.2), p = 0.0017, Fig. 5b). By differentiating
a
b
Fig. 3 ADAMTS19 hypermethylation and CRC clinicopathological characteristics (a) and tumor genotype (b). Tumor stage is indicated using the
Dukes’ classification, grouping A and B vs. C and D. WT wild type, MUT mutated. P values were calculated by Fisher’s exact test
a
b
c
Fig. 4 ADAMTS19 hypermethylation incidence in primary tumors of different origins in tumors from our collection (a) and from the TCGA
datasets (b). In blue are ADAMTS19 hypermethylated cases. A higher incidence is found in gastrointestinal cancers compared to ovary and breast
cancers (p = 5.2 × 10−7, OR = 2.9, CI = (1.9–4.7), Fisher’s exact test). c ADAMTS19 hypermethylation associates with mucinous phenotype in CRC and
ovarian cancers (p = 0.023 and p = 4 × 10−16, respectively, Fisher’s exact test). The three ovarian cancer cases with ADAMTS19 hypermethylation in
the no mucinous group were the only three clear-cell adenocarcinomas
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between distal and local metastases, inverse trends be-
came significant. Thus, methylation decreased from non-
metastatic CRCs (Dukes’ A + B) to metastatic CRCs
(Dukes’ C + D) to metastases to the liver and lung (p =
0.031, Cochran-Armitage test) (Fig. 5c). Inversely, asso-
ciation with the depth of invasion revealed an increased
incidence of methylation in more invasive tumors and
their corresponding local metastases (p = 0.030, Cochran-
Armitage test) (Fig. 5d).
Methylation associates with gene silencing and
demethylation restores ADAMTS19 expression
Genomic DNA from Colo205, DLD1, HCT8, HCT15,
HCT116, HT29, LoVo, LS180, SW48, and SW480 CRC
cell lines was treated with bisulfite, polymerase chain reac-
tion (PCR) amplified, and cloned. Five plasmid clones
from each cell line were isolated and sequenced. The
results revealed different methylation patterns with some
of the cell lines heavily methylated, while others were es-
sentially unmethylated (Additional file 1: Figure S4). The
expression level of ADAMTS19 in these cell lines was ana-
lyzed by quantitative reverse transcription polymerase
chain reaction (RT-PCR). Cell lines with full methylation
of ADAMTS19 CGI did not exhibit detectable levels of ex-
pression. Some of the cell lines with intermediate levels of
methylation expressed the gene at very low level, but
the highest level of expression corresponded to the
fully demethylated cell lines DLD1/HCT15 and SW480
(Additional file 1: Figure S4). We studied the association
between methylation and transcriptional levels by
treating these cell lines with the demethylating agent
5-AZA-2-deoxycytosine (AdC). After 48 h of treatment,
ADAMTS19 expression was analyzed by RT-PCR. The re-
sults confirmed that pharmacological demethylation with
AdC restored expression in the four fully methylated cell
lines (HT29, SW48, Colo205, and HCT116) (Additional
file 1: Figure S4).
ADAMTS19 downregulation reduces the migration
capabilities of CRC cells
To investigate the phenotypic effect of ADAMTS19 si-
lencing, we performed knockdown experiments with
interference RNA (shRNA) in DLD1 and SW480 cell
lines, having no methylation and exhibiting the highest
levels of expression (Additional file 1: Figure S4b). We
designed three different specific shRNAs targeting exons
3, 13, and 22 (shA19e3, shA19e13, and shA19e22, re-
spectively). These shRNAs were transfected into SW480
and DLD1 separately and in different combinations. As
negative controls, cells were transfected with vectors
a b
c d
Fig. 5 ADAMTS19 hypermethylation and CRC tumor progression and invasion. a Incidence of ADAMTS19 hypermethylation in adenomas (ADE),
primary CRCs (grouping Dukes’ A + B and C + D), and metastases (MET). b Incidence of ADAMTS19 hypermethylation in Dukes’ D primary cancers
that metastasized to distant (mostly the liver or lung) or to local (mostly the ovary or omentum) organs and in metastases (MET). c Incidence of
ADAMTS19 methylation vs CRC progression in primary cancers (Dukes’ scale, grouping A/B and C/D). d Incidence of ADAMTS19 methylation and
depth of invasion in primary cancers (TNM scale, grouping T1/2 and T3/4). P values were calculated by Fisher’s exact test (b) and by Cochran-Armitage
test for trends (a, c, and d)
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containing shRNA targeting luciferase (shLuc) or GFP
(shGFP1 and shGFP2) genes, both absent in these cells.
Transfected cells were selected by culture with puro-
mycin. ADAMTS19 transcriptional levels were analyzed
by RT-PCR to determine the efficiency of these shRNAs
in stably transfected cells. The most efficient silencing
was achieved with shA19e22, which downregulated the
levels of expression of ADAMTS19 to less than 30 % of
untreated levels in SW480 (Additional file 1: Figure S5).
Similar results were obtained in DLD1. To investigate
whether some subclones achieved even stronger down-
regulation, 10 subclones of the shA19e22 transfected
SW480 cells were isolated and individually evaluated for
ADAMTS19 expression. These subclones exhibited little
deviation from the silencing level measured in the cell
pool (Additional file 1: Figure S5).
ADAMTS19 silencing did not affect the in vitro growth
rate or anchorage-free growth capabilities (Additional file 1:
Figure S6) of ADAMTS19-downregulated SW480 cells.
We also studied changes in invasion potential in vitro
by Matrigel-coated Transwell assays. However, the only
parental cell lines with high expression of ADAMTS19
(DLD1/HCT15 and SW480) exhibited very low capabil-
ity to migrate through the Matrigel layer (averaging 1
or 2 cells per view field), yielding no statistically significant
observable difference between the cells with and without
knockdown of gene expression (not shown). However, we
found a significant reduction in the migratory capabilities
of SW480 cells upon ADAMTS19 downregulation, mea-
sured by two complementary methods, i.e., wound healing
(Additional file 1: Figure S7) and collagen I coated Trans-
well assays (Fig. 6).
Discussion
We were intrigued by the observation that ADAMTS19
hypermethylation was the most common epigenetic alter-
ation observed in gastric and colorectal cancers among
the many loci analyzed by unbiased MS-AFLP fingerprint-
ing. The rationale to investigate this finding in more depth
seemed justified because of the established role of
ADAMTS proteins in tumorigenesis, and at the same
time, the unexplored nature of the ADAMTS19 in the
process. Once the fingerprinting observation was validated
by direct bisulfite sequencing and other complementary
epigenomic techniques, we explored in a descriptive study
the involvement of this somatic epigenetic alteration in
several malignancies. The results showed a specific associ-
ation with gastrointestinal cancers that was corroborated
by in silico analysis of the public TCGA data. Methylation
also associated with silencing and demethylation in vitro
by azacytidine restored expression.
We then correlated the methylation alterations with
clinicopathological and genetic parameters in CRC. No
significant associations were found with any of the
demographic, pathological, or genetic data analyzed ex-
cept with the MSI status and mutations in BRAF (most of
them MSI cancers, Fig. 2). This is consistent with previous
observations showing that BRAF-mutant CRCs exhibit a
higher frequency of somatic CGI hypermethylation.
When analyzed in relation to metastatic spread, methy-
lation showed a much lower association with metastases
homing to distant (i.e., the lung and liver) organs in com-
parison with those metastases to local organs such as the
ovary and omentum. Finally, in an effort to find a connec-
tion genotype-phenotype, we studied several cellular phe-
notypes related to cell growth and migration. The results
overall are not conclusive, and the putative role in CRC
pathogenesis of the epigenetic silencing of ADAMTS19 re-
mains to be established. However, we have several clues
Fig. 6 Silencing of ADAMTS19 with shA19e22 reduces the migration
capabilities of SW480 cells. Transwell migration assay using a matrix
of collagen I. Experiments were performed in three independent
replicates, using three wells per cell line in each replicate, and
examining three to six microscope fields per well. No statistically
significant difference was detected between replicates. In gray are
boxplots combining all the values per cell line. In orange are
boxplots showing the values of individual wells in controls (SW480
and SW480 transfected with shLuc) and in blue the ADAMTS19-
silenced cell line SW480 transfected with shA19e22. A 35.8 %
reduction of median migratory capabilities was observed in SW480
cells transfected with shA19e22. P values were calculated by Tukey’s
honest significance method on a nested ANOVA model
Alonso et al. Clinical Epigenetics  (2015) 7:124 Page 9 of 15
that point to an active contributory role in CRC tumor
progression.
First, the tumor-specific somatic hypermethylation does
not appear to be a random and general epiphenomenon
because it is restricted to gastrointestinal malignancies, as
it is essentially absent in ovarian and breast cancers.
Moreover, methylation associates with the manifestation
of the mucinous phenotype in CRC and especially in ovar-
ian cancer. The striking association between ADAMTS19
methylation and the mucinous phenotype in ovarian can-
cers, a subtype of cancer of difficult diagnosis due to its
resemblance to secondary lesions of colorectal origin,
opens a number of avenues for further investigation with
potential diagnostic applications.
Second, methylation is not consequence of a local epi-
genetic disturbance in the genome driven by a nearby
“culprit” gene. This conclusion is supported by the dis-
continuous map of hypermethylation in the ADAMTS19
region and the absence of association between methyla-
tion of ADAMTS19 and any of the adjacent genes, some
of which are indeed methylated in CRC even with higher
frequency (Fig. 2). In particular, FBN2, is an obvious
candidate for the targeted hypermethylation of this
chromosomal region because mutations in the gene have
been linked to Marfan-like syndromes [49] and because
hypermethylation has been reported as a biomarker in
CRC and other cancers [50–52]. However, notwithstand-
ing a putative independent role of FBN2 in CRC, we
conclude that FBN2 is not the main target for inactiva-
tion because of the following considerations: Methyla-
tion of this gene is not specific for tumor cells as it
shows some weaker methylation in normal tissue, which
is not the case for ADAMTS19 (Fig. 2). Moreover, FBN2
is not included in the microdeletion of this chromo-
somal region present in one of the CRCs analyzed by
array CGH that targets only the ADAMTS19 gene and
the very few adjacent genes. The result is conclusive be-
cause a polymorphic CA repeat located outside the
FBN2 gene retained heterozygosity in this tumor, show-
ing that FBN2 was not affected by the microdeletion
(Additional file 1: Figure S2). This microdeletion also
adds evidence for the existence of a selective pressure
for the loss of ADAMTS19 in the early stages of CRC.
In contrast with the absence of association between
hypermethylation of FBN2 and ADAMTS19, there is a coor-
dinated hypermethylation of this metallopeptidase and other
members of the ADAMTS gene family that extends across
the genome (data not shown). The mechanism underlying
this intriguing trans-acting positive correlation in ADAMTS
methylation is inexplicable at the moment and deserves
further analysis. Nevertheless, it also serves as a compara-
tive control over the lack of correlation with the genes ad-
jacent to ADAMTS19, showing that the gene is a target in
itself for somatic hypermethylation in a subset of CRC.
Third, the most direct evidence for a functional role of
ADAMTS19 hypermethylation is the observed pheno-
typic changes after downregulation of its expression.
This proves that silencing is not inconsequential. How-
ever, there is no sufficient data to provide a clear picture
of the actual role of ADAMTS19 and its epigenetic alter-
ation in CRC tumorigenesis because of the complex fea-
tures so far emerging of its involvement. Silencing and
downregulation accompanied by inhibition of migration
is not easily reconciled with a functional role in tumor
progression. However, the asymmetries observed in the
incidence of methylation during tumor progression and
metastatic spread may indeed provide some potential ex-
planations. A positive selection for cells with a methyl-
ated and silenced gene during the early stages of CRC
development may be followed by a reverse selection in
more advanced stages of tumor invasion and progres-
sion. This also is to be understood in the context of the
different behavior of the epigenetic alterations depending
on the different parameters ruling tumor progression:
There appears to be a negative association with stage of
progression but a positive association with the depth of
invasion (Fig. 5). Similarly, there is a decreased of inci-
dence in methylation in distant hepatic and lung metas-
tases but an increased incidence of local metastases such
as the ovary and omentum (Fig. 5).
ADAMTS19 hypermethylation frequency was higher in
adenomas (47.6 %) than in carcinomas (34.6 %) or me-
tastases (30.9 %). Considering MSS tumors only, the re-
sults were essentially the same, 50 % in adenomas,
32.4 % in adenocarcinomas, and 29.5 % in metastases,
revealing an asymmetry between premalignant and ma-
lignant tumors (OR = 0.47, CI = (0.22–0.97), p = 0.031).
This suggests that ADAMTS19 hypermethylation could
be detrimental for tumor progression, i.e., adenomas
with ADAMTS19 hypermethylation would be less likely
to become malignant or carcinomas less metastatic.
However, our data is the endpoint analysis of different
samples and does not necessarily represent an accurate
time-course of the adenoma-carcinoma-metastasis pro-
gression. The cases with primary-metastases from the
same CRC patients were too few to reach meaningful
conclusions in this regard, but to increase the sample
size of these cases is an obvious course of action in the
future.
The main difficulty in proposing a coherent model for
the role of ADAMTS19 hypermethylation in CRC resides
in the generally accepted irreversibility of aberrant
hypermethylation. Why a gene that undergoes hyperme-
thylation early on during tumorigenesis would have a
drop in methylation incidence later on the process is not
altogether clear. For the reasons discussed before, the
first “passenger” hypothesis to explain methylation as in-
consequential seems unlikely. The simplest explanation
Alonso et al. Clinical Epigenetics  (2015) 7:124 Page 10 of 15
for a functional role of hypermethylation is that the pri-
mary tumor may be heterogeneous for methylation sta-
tus, with the cells that eventually disseminate and
colonize the liver, for instance, coexisting unmethylated
in the primary tumor with other methylated sister cells.
In support of this hypothesis, some of the clones from
ADAMTS19 methylation-positive tumor samples ana-
lyzed by bisulfite sequencing (Fig. 1b) were essentially
unmethylated, resembling the methylation pattern of
the normal tissue. The most likely explanation is that
ADAMTS19 methylation is heterogeneous in the cell
population. In addition to contamination with normal
cells (obligated in primary tumor samples), non-clonal
methylation may account for this heterogeneity.
Our in vitro studies indicate that ADAMTS19 down-
regulation reduces the motility of cancer cells (Fig. 6 and
Additional file 1: Figure S7), suggesting that ADAMTS19
hypermethylated cells could be less capable to escape
the tumor mass and migrate to distant organs through
the vascular system. This effect was observed despite the
fact that shRNA-induced downregulation did not com-
pletely silence ADAMTS19 transcription. The analysis of
mRNA expression in cell lines (Additional file 1: Figure S4)
suggests that promoter hypermethylation has a stronger
downregulation effect. Therefore, it is possible that in vivo
ADAMTS19 hypermethylation exerts a stronger negative
effect on the migration capabilities of tumor cells. This hy-
pothesis predicts that some of the clonally methylated tu-
mors will generate methylated metastases, preferentially to
local organs (the ovary or omentum), while other tumors
non-clonal for methylation will generate unmethylated me-
tastases preferentially to distant organs (the liver or lung).
While metastatic spread to distant organs involves intra-
and extravasation, the dissemination into the peritoneal
cavity may occur by direct spread of floating tumor cells
once the primary tumor invades and penetrates through
the colon wall. Inhibition of migration would not hamper
the metastatic dissemination in this context. This is most
likely an over-simplifying hypothesis but at least provides a
working model for the differences in metastatic homing by
the cells with and without ADAMTS methylation.
Conclusions
In summary, our results demonstrate that the promoter of
ADAMTS19 is targeted by hypermethylation in a signifi-
cant proportion of gastrointestinal cancers, particularly in
BRAF-mutant cancers, and that this hypermethylation as-
sociates with transcriptional downregulation and reduces
the in vitro migration capabilities of CRC cells. The link
between methylation of this gene and altered in vivo
migration and invasion capabilities of metastatic cells re-
mains to be established. A more detailed study with ani-
mal model systems for metastasis of CRC seems an
obvious approach. All together, our findings reinforce the
emerging role of extracellular matrix homeostasis disrup-
tion as a relevant event in cancer progression in general
and CRC in particular [8, 53, 54].
Methods
Cell lines and human tissues
Freshly frozen human cancers and normal matching tis-
sues (from each one of the patients) were obtained from
the Cooperative Human Tissue Network [55]. Colon
cancer cell lines Colo205, DLD1, HCT8, HCT15,
HCT116, HT29, LoVo, LS180, SW48, and SW480 were
obtained from the American Type Culture Collection,
Rockville, MD, USA. Cell lines were authenticated by
STR profiling using Identifiler Plus PCR Amplification
kit (Life Technologies). DLD1 and HCT15 cell lines are
in fact the same, as they were derived from the same
tumor, although due to their mutator phenotype they
harbor several genotypic differences [56]. Sanford-
Burnham Institutional Review Board approved the re-
search protocol, which was in compliance with national
legislation and performed according to the ethical guide-
lines of the Declaration of Helsinki [57].
Cell culture conditions
Cells were cultured in DMEM-F12 (Life Technologies) sup-
plemented with fetal bovine serum 10 % (v/v), antibiotics,
and antimycotics on 100 mm culture dishes in a 37 °C incu-
bator with 5 % CO2. Unless otherwise indicated, cells were
grown until reaching 80–90 % confluency before collection.
When needed, 5-aza-2′-doexycytidine (5AdC) was added
to the culture media at a final concentration of 1 μM.
DNA methylation analyses
MS-AFLP was performed as previously described, using
primer NotI + G in three separate combinations with
primers MseI + CA, MseI + CG, and MseI + C [45, 58].
We used a SacII-based quantitative analysis for methyla-
tion, a method similar to MethylScreen [46], with some
modifications. Briefly, genomic DNA was first sheared
by digestion with EcoRI at 37 °C during 2 h. Then the
sample was divided into two aliquots. One of them was
treated with the methylation-sensitive enzyme SacII at
37 °C for 4 h, while the other was subjected to the same
incubation but in the absence of restriction enzyme.
Then, the percentage of methylated molecules was esti-
mated as the proportion of DNA molecules resistant to
digestion in the SacII-treated aliquot, evaluated by quan-
titative PCR in a LightCycler 480 System (Roche), with
primers P28 and P29 (see Additional file 1: Table S1),
and using the SacII-untreated aliquot as reference. For bi-
sulfite sequencing [47, 48] and combined bisulfite and re-
striction analysis (COBRA) [59], 1 μg of genomic DNA was
treated with bisulfite (EZ-methylation kit, Zymo Research).
Human methylated and non-methylated DNA standards
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(Zymo Research) were used as controls. After bisulfite
treatment, the promoter region of ADAMTS19 was ampli-
fied by a two-step nested PCR. Conditions for the first
amplification step were 100 ng of bisulfite-treated DNA as
template, primers P44 and P46 at a final concentration of
0.4 μM each, dNTPs at 0.125 μM each, Q-Solution 0.5X,
and one unit of Hotstart DNA Polymerase (Qiagen) in a
total volume of 20 μL. The PCR program consisted of
1 cycle at 95 °C for 5 min to activate the enzyme, followed
by 35 cycles of denaturation at 95 °C for 5 s, annealing at
55 °C for 30 s, and extension at 72 °C for 60 s, ending at
72 °C for 5 min to complete extension. The product of the
first amplification was diluted 1:20 (v/v) in TE 0.1X (Tris ·
HCl 1 mM, EDTA 0.1 mM, pH 8.0). One microliter of the
dilution was used as template for a second reaction using
identical conditions but with primers P16 and P45. Shorter
PCR programs, using as low as 20 + 25 cycles yielded essen-
tially identical results. The nested PCR generated a single
amplicon of 331 bp. For COBRA analysis, 5 μL of PCR
product were treated for 1 h with BstUI (New England Bio-
labs) at 60 °C or with its isoschizomer Bsh1236I (Thermo
Scientific) at 37 °C, both recognizing the 5′-CGCG-3′ se-
quence. In parallel, 5 μL of the PCR product were subjected
to incubation in the same conditions but in the absence of
restriction enzyme. After digestion, samples were resolved
by electrophoresis in 2 % (w/v) agarose gels or, in some
cases that required higher sensitivity, in 8 % acrylamide/
bisacrylamide (29:1) vertical gels. After electrophoresis, gels
were stained with ethidium bromide and visualized in a
GelDoc XR system (Biorad). Methylation was determined
by the presence of digestion products in the restriction
enzyme-containing reaction that indicate the presence of
originally methylated CGCG sites resilient to the bisulfite
conversion. For bisulfite sequencing, 1 μL of PCR product
was cloned into pCR2.1-TOPO vector (Invitrogen) follow-
ing manufacturer’s instructions and transformed into E. coli
TOP10 competent cells. Transformed cells were selected
onto LB plates containing Ampicillin (50 μg/mL) and X-
Gal (40 μg/mL). Ten to 20 white colonies were selected for
plasmid preparation (QIAprep miniprep kit, Qiagen, CA).
The plasmid inserts were sequenced using primers M13-
forward and M13-reversal (Qiagen). Array-based methylation
analyses were performed on Infinium HumanMethyla-
tion450 BeadChip arrays and scanned in a HiScanSQ
system (Illumina, CA), following the manufacturer’s in-
structions. Bioinformatic analysis was performed using
RnBeads package [60].
Gene expression analyses
To analyze ADAMTS19 mRNA levels, total RNA was ex-
tracted using TRIzol Reagent (Invitrogen, Life Technologies)
and used as template to synthesize cDNA using Superscript-
II reverse transcriptase (Invitrogen, Life Technologies) with
random hexamers for priming. We designed two primers
that anneal in exon 20 (primer PB176) and exon 21 (primer
PB177), generating a 242 bp amplicon. The amplification
was quantified in real time using SYBR-Green Master Mix
in a Lightcycler LC480-II System (Roche, CA). After 40 cy-
cles, the specificity of the amplification was verified by
melting curve analysis, and the amplicon size was subse-
quently confirmed by electrophoresis in 2 % (w/v) agarose
gels. All reactions were performed in duplicate. Expression
levels were calculated using the 2−ΔΔCt method combining
both GAPDH and TPT1 as normalization genes. In all reac-
tions, efficiency was very close to 2 within the range of con-
centrations assayed.
Microallelotyping and array CGH analyses
Copy number alterations were analyzed by microallelotyp-
ing using polymorphic dinucleotide microsatellite markers
D5S642 and D5S2057, located 0.6 Mb centromeric and
1.8 Mb telomeric of ADAMTS19. In some cases where
both markers were in homozygosis, we also analyzed
D5S2098, located 5 Mb upstream of ADAMTS19. Primer
sequences to amplify these markers were obtained from
the Ensembl website [61]. PCR amplification was per-
formed in presence of α-32P-dCTP and resolved in vertical
electrophoresis acrylamide-bisacrylamide gels. After elec-
trophoresis, gels were dried and exposed to X-ray films.
Loss of heterozygosity was assessed in heterozygous cases
by the relative change in intensity in one of the bands
when comparing the normal and tumor sample. aCGH
was performed using Agilent 44K arrays, following the
manufacturer’s protocol. Copy number alterations were
analyzed using Agilent Genomic Workbench, with ADM-
2 algorithm, threshold of 6, and Fuzzy Zero correction.
Only alterations with a minimum of three consecutive
probes were considered valid.
shRNA design and transfection
Three pairs of oligos coding for the shRNAs and targeting
ADAMTS19 exons 3 (Exon3-F and Exon13-R), 13 (Exon13-
F and Exon13-R), and 22 (Exon22-F and Exon22-R) were
designed using the web server from Life Technologies [62]
(Additional file 1: Table S1). Two hundred picomole of
every primer pair was annealed by incubation at 95 °C for
4 min and a stepwise cooling of 5 °C every 4 min down to
40 °C. The annealed oligos were cloned into pSUPER
(RNAi system, oligoengine) following the manufacturer’s in-
dications. After cloning, the shRNA-containing plasmids
were purified and transfected into the target cells using
GeneJuice Transfection Reagent (Novagen). Stable trans-
fected cells were selected by culturing in the appropriate
culture medium supplemented with 5 μg/mL puromycin.
In vitro proliferation assay
Cell proliferation was measured using a colorimetric test
based on the capability of metabolic active cells to cleavage
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the yellow tetrazolium salt (XTT) to form a soluble orange
formazan dye tetrazolium salt (Cell Proliferation Kit II
XTT, Roche). Briefly, the cells were plated in 96-well micro-
titer plates at a density of 2 × 104 cells/well in Dulbecco’s
modified Eagle’s medium (DMEM) medium with 10 % fetal
bovine serum (FBS) and cultured at 37 °C for 0, 12, 24, 48,
and 72 h in a humidified atmosphere of 5 % CO2. Then,
50 μl of XTT was added to each well and incubated for 4 h
at 37 °C in the presence of 5 % CO2. After the incubation
with XTT, the optical density was measured at 492 and
690 nm using a plate reader. The amount of metabolic ac-
tive cells was estimated by subtracting the OD690nm value
to the OD492nm value, as indicated by the kit manufacturer.
In vitro anchorage-free growth assay
Cells were suspended in growth media containing 0.3 %
(w/v) agarose at 5 × 103 cells/ml and layered over 1 % (w/v)
agar in growth media in 35 mm plates. The agar was
allowed to solidify at room temperature for 20 min before
incubating the cells at 37 °C and 5 % CO2. After 21 days,
colonies were stained with 0.5 % (w/v) Crystal Violet (0.5 %)
in 10 % (v/v) ethanol, then photographed, and counted. All
the samples were assayed in triplicate, and in each replica, a
minimum of three fields were counted and averaged.
In vitro migration assay
Cell migration was assayed by two complementary
methods: scratch/wound healing assays and Transwell
plates (8 μm pore size) (Millicell, Millipore). For the
scratch/wound healing assays, cells were cultured until
reaching confluency and then four different scratches
were done using a P200 micropipette tip. The width (in
µm) of the scratches was measured at different positions
using an automatized-capture Leica DMI 6000 B micro-
scope. After 24 h of incubation, the width was measured
again at the same coordinates that were previously stored
in the microscope managing software. The collective mi-
gration speed was estimated dividing the difference in the
scratch width by two, and then by 24h (see equation in fig-
ure S7). Clumps or colonies of cells inside the scratch but
disconnected from the borders of the scratch were ig-
nored. The experiments were performed in duplicate. For
the Transwell plate assays, the undersurface of the mem-
brane was coated at 4 °C overnight with 40 μg/mL of Col-
lagen I (BD Bioscience, cat N. 354236) diluted in PBS and
then blocked with 2 % (w/v) BSA at room temperature for
2 h. The upper compartment was seeded with 2 × 105 o/n
starved transfected cells per well in 200 μL of serum-free
DMEM + 0.5 % BSA. DMEM + FBS (10 %) was added in
the lower chamber. Cells were allowed to migrate through
the membrane for 21 h. Cells capable of migrating
through the membrane were stained with 0.5 % (w/v)
Crystal violet (Sigma) in 10 % (v/v) ethanol. Each experi-
ment used quadruplicate wells and, within each well,
counting was performed in six randomly selected micro-
scopic high-power fields (100×).
In vitro invasion assay
Cells stably transfected with the shRNAs were starved over-
night in serum-free DMEM and then loaded into Matrigel
invasion chambers (24 wells, BD Biocoat Matrigel invasion
chamber, BD Biosciences) at a density of 2.5 × 104 cells/
well, according to the manufacturer’s instructions. Cells
were allowed to invade for 24 h, and then invasive cells
were fixed and stained with 0.5 % (w/v) Crystal violet in
10 % (v/v) ethanol and counted using an inverted micro-
scope (Leica, McBain Instruments, Chatsworth, CA). Each
experiment used quadruplicate wells, and within each well,
counting was performed in six randomly selected micro-
scopic high-power fields (100×).
Analysis of the TCGA data
Methylation status of ADAMST19 CGI was downloaded
from the methHC webserver [63]. Methylation data of
the TCGA ovarian cancer dataset is not included in
methHC because most cases have been analyzed with
the HM27K platform. Hence, this dataset was directly
downloaded from the TCGA. COAD (colon) and READ
(rectum) datasets were combined into a single dataset,
representing colorectal carcinomas (CRC).
Statistical analysis
Statistical analyses were performed using the R statistical
environment [64]. Association between two categorical
variables was analyzed by Fisher’s exact test (for 2 × 2 con-
tingency tables) or chi-square test (for larger contingency
tables). Normality of continuous variables was assessed
using the Shapiro-Wilk test. Comparisons between two
groups were performed with the Student’s t test for vari-
ables following a normal distribution or with the non-
parametric Mann-Whitney-Wilcoxon test for variables
that do not follow a normal distribution. When more than
two groups were analyzed, we applied ANOVA or
rANOVA analyses followed by Tukey’s honest significant
difference method. Trend analysis of categorical data was
performed using the Cochran-Armitage test. The level of
statistical significance was set at p < 0.01, unless otherwise
specified. Holm’s multi-hypothesis testing correction was
applied when appropriate [65].
Additional file
Additional file 1: Figures S1–7 and Table S1. Validation of the
methylation alterations in ADAMTS19, array CGH analysis of Chr5, association
of ADAMTS19 with clinicopathological parameters, methylation and
expression of ADAMTS19 in CRC cell lines, silencing of ADAMTS19 expression
using shRNA constructs, effect of ADAMTS19-silencing on growth rate and
anchorage free growth, effect of ADAMTS19-silencing on collective cell
migration speed, and sequence of primers used in this study.
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